Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2020-02, Vol.145 (2), p.AB71
Main Authors: Sleasman, John, Lumry, William, Hussain, Iftikhar, Wedner, H. James, Harris, James, Mondou, Elsa, Lin, Jiang, Hames, Carrie, Querolt, Montse, Stein, Mark
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0091-6749
DOI:10.1016/j.jaci.2019.12.648